Fairer Vaccine Access Could Save Millions of Lives in a Future Pandemic

A new global health analysis has highlighted the enormous human cost that unequal access to vaccines could create during a future pandemic, suggesting that substantially more lives could be protected if vaccines and other critical medical tools were distributed more equitably between countries.

The analysis estimates that nearly three million additional deaths could potentially be prevented during a future pandemic if vaccines were shared more fairly. The finding has renewed attention on one of the central lessons from the COVID-19 pandemic: developing a vaccine is only one part of pandemic preparedness. Ensuring that people in different parts of the world can actually obtain it in time is equally important.

The issue is particularly significant for countries with limited healthcare resources, where vaccine shortages can coincide with weaker medical infrastructure, fewer intensive-care facilities and reduced capacity to respond to rapidly expanding outbreaks.

Vaccine Development Alone Is Not Enough

Modern medicine has demonstrated that vaccines can sometimes be developed remarkably quickly when governments, scientists and manufacturers work together.

But producing a vaccine does not automatically mean that every country receives sufficient supplies.

During a global health emergency, countries with greater financial resources may be able to negotiate large purchases, secure manufacturing capacity and establish delivery agreements earlier.

Lower-income countries can subsequently face delays.

This creates a gap between scientific progress and practical access.

A vaccine sitting in a manufacturing facility cannot protect someone until it reaches the community, is stored appropriately, administered and followed by the required doses when necessary.

The Pandemic Experience Revealed Major Inequalities

The COVID-19 pandemic exposed significant differences in vaccine availability between countries.

While vaccination programmes expanded rapidly in wealthier nations, many poorer countries struggled to obtain adequate supplies during critical stages of the pandemic.

The disparity was not simply a question of whether vaccines existed. Timing was also crucial.

Receiving vaccines months after a major wave has passed can have a very different public-health effect from receiving them before transmission accelerates.

This makes the design of international vaccine-sharing mechanisms an important component of pandemic preparedness.

Timing Can Determine the Value of a Vaccine

The potential benefit of a vaccine depends heavily on when it reaches the population.

Suppose a country receives substantial vaccine supplies after a virus has already infected a large proportion of its population. The vaccine can still protect people who remain susceptible, but some of the opportunity to prevent severe illness and deaths during the initial wave may already have been lost.

By contrast, rapid access before or during the early phase of an outbreak can potentially reduce transmission and protect high-risk groups.

This is why manufacturing capacity and distribution agreements need to be established before a pandemic rather than negotiated only after a crisis begins.

Manufacturing Capacity Is a Strategic Issue

Global vaccine equity is closely connected to where vaccines are manufactured.

If production is concentrated in a relatively small number of countries, disruptions at manufacturing facilities or restrictions on exports can have international consequences.

Expanding manufacturing capacity across different regions could reduce dependence on a limited number of production centres.

Regional manufacturing can also shorten delivery routes and potentially improve the speed at which vaccines reach nearby populations.

However, building vaccine factories requires investment, skilled workers, regulatory systems, reliable supply chains and sustained demand.

Raw Materials Can Become a Bottleneck

Even when manufacturing plants exist, vaccine production depends on complex international supply chains.

Specialized ingredients, containers, filters, equipment and other components may come from different countries.

A global emergency can place extraordinary pressure on these supply networks.

If one critical component becomes unavailable, production can slow even when the main manufacturing facility has sufficient capacity.

Pandemic preparedness therefore requires attention not only to finished vaccines but also to the broader industrial infrastructure supporting production.

Intellectual Property Is Part of the Debate

The question of vaccine access also involves intellectual property.

Vaccines often depend on proprietary technologies, manufacturing processes and specialized knowledge.

Supporters of stronger intellectual-property protections argue that these rights can encourage investment in research and development.

Public-health advocates have argued that exceptional emergencies may require mechanisms that allow technology and manufacturing know-how to be shared more broadly.

The challenge is finding arrangements that preserve incentives for innovation while ensuring that lifesaving technologies can reach populations during global emergencies.

International Agreements Could Change the Response

Governments and international organizations have been working on mechanisms intended to improve preparedness for future pandemics.

A key objective is to establish rules before the next major outbreak occurs.

Such arrangements can address questions including vaccine allocation, technology transfer, financing, surveillance, manufacturing capacity and information sharing.

The advantage of establishing these mechanisms in advance is that countries do not have to negotiate every issue while simultaneously dealing with rapidly increasing infections.

Equity Is Also an Epidemiological Issue

Fair vaccine distribution is not only a question of international solidarity.

It can also affect the trajectory of an outbreak.

If a virus continues circulating extensively in under-vaccinated populations, opportunities remain for transmission and for the emergence of new variants.

Not every new variant will be more dangerous or more transmissible, but continued viral circulation increases the number of opportunities for evolutionary change.

Protecting populations across different regions can therefore contribute to broader global disease control.

Healthcare Capacity Makes the Difference Even Greater

Vaccine availability is particularly important where healthcare systems have limited capacity.

A severe outbreak can rapidly overwhelm hospitals when there are insufficient intensive-care beds, medical oxygen, healthcare workers or diagnostic facilities.

Preventing infections and severe disease through vaccination can reduce pressure on hospitals.

In countries with stronger healthcare systems, a large outbreak can still cause serious disruption, but there may be greater capacity to expand treatment.

In resource-constrained settings, even a comparatively smaller increase in hospital demand can have significant consequences.

Funding Remains a Major Question

Creating a more equitable global vaccine system requires financing.

Manufacturing facilities need long-term investment. Research programmes require funding before an emergency occurs. Stockpiles need to be maintained, and distribution networks need to remain functional.

One difficulty is that pandemic preparedness often receives less political attention between emergencies.

Governments may be reluctant to spend heavily on systems whose benefits become most visible only when a crisis occurs.

The COVID-19 experience demonstrated the cost of insufficient preparation, but maintaining preparedness over the long term remains a policy challenge.

Technology Transfer Could Strengthen Regional Preparedness

Sharing technical knowledge can help countries develop their own manufacturing capabilities.

Technology transfer may include training, production processes, quality-control systems and regulatory expertise.

Developing regional capacity does not necessarily mean every country needs to manufacture every type of vaccine.

Instead, groups of countries could build complementary production networks, reducing dependence on a small number of suppliers.

Such systems could become particularly valuable during a pandemic when global demand suddenly rises.

Vaccines Are Only One Part of Pandemic Preparedness

The analysis should also be viewed within the broader context of pandemic preparedness.

Vaccines cannot replace disease surveillance, diagnostic testing, effective healthcare systems, infection-control measures and rapid communication.

A country may have access to vaccines but still experience serious consequences if infections are detected too late or medical facilities become overwhelmed.

Preparedness therefore needs to operate across multiple levels.

Early warning systems can identify emerging threats, laboratories can confirm infections, researchers can develop medical countermeasures, and health systems can deliver them to people who need them.

The Next Pandemic Will Not Necessarily Resemble COVID-19

Future pandemics could involve very different pathogens.

A respiratory virus, for example, can spread differently from a disease transmitted through contaminated food, insects or direct contact.

The speed of vaccine development may also vary depending on the pathogen.

For that reason, pandemic preparedness systems need flexibility rather than relying exclusively on lessons from one disease.

Nevertheless, equitable access to medical countermeasures is likely to remain an important factor regardless of the specific pathogen involved.

A Global Health Lesson With Long-Term Consequences

The estimate of millions of potentially preventable deaths illustrates the scale of the stakes involved in pandemic vaccine distribution.

The underlying lesson is straightforward: scientific breakthroughs have their greatest public-health value when they reach people quickly and at sufficient scale.

Improving global preparedness therefore requires countries to look beyond vaccine research alone.

Investment in manufacturing, technology sharing, supply chains, financing, regulatory cooperation and international distribution mechanisms could help reduce the inequalities that emerged during previous health emergencies.

The next pandemic cannot be predicted with certainty, but its consequences will depend partly on decisions made before it begins.

Ensuring that lifesaving vaccines can reach populations across income levels and geographic regions could become one of the most consequential elements of future global health preparedness.